1-Methyl-1,2,3,4-tetrahydroisoquinoline antagonizes a rise in brain dopamine metabolism, glutamate release in frontal cortex and locomotor hyperactivity produced by mk-801 but not the disruptions of prepulse inhibition, and impairment of working memory in rat

Neurotoxicity Research

Volumn 16, Issue 4, 2009, Pages 390-407

  Pietraszek, Malgorzata ^a   Michaluk, Jerzy ^a   Romańska, Irena ^a   Wa̧sik, Agnieszka ^a   Golembiowska, Krystyna ^a   Antkiewicz Michaluk, Lucyna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

1MeTIQ; Dopamine; Locomotor activity; Prepulse inhibition; Schizophrenia; Working memory

Indexed keywords

1 METHYL 1,2,3,4 TETRAHYDROISOQUINOLINE; 3 O METHYLDOPAMINE; 3,4 DIHYDROXYPHENYLACETIC ACID; DIZOCILPINE; DOPAMINE; GLUTAMIC ACID; HOMOVANILLIC ACID; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG; 1-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINE; DIZOCILPINE MALEATE; DOPAMINE RECEPTOR BLOCKING AGENT; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE RELEASE; DRUG MECHANISM; DRUG SCREENING; FRONTAL CORTEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERACTIVITY; MALE; MEMORY DISORDER; NEGATIVE SYNDROME; NEUROCHEMISTRY; NONHUMAN; POSITIVE SYNDROME; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; WORKING MEMORY; ANALYSIS OF VARIANCE; ANIMAL; AUDITORY STIMULATION; BRAIN; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; HYPERKINESIA; INHIBITION (PSYCHOLOGY); MAZE TEST; METABOLISM; METHODOLOGY; MICRODIALYSIS; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; STARTLE REFLEX; WISTAR RAT;

ANIMALIA; MAMMALIA; RATTUS; RODENTIA;

ACOUSTIC STIMULATION; ANALYSIS OF VARIANCE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GLUTAMIC ACID; HYPERKINESIS; INHIBITION (PSYCHOLOGY); MALE; MAZE LEARNING; MEMORY DISORDERS; MICRODIALYSIS; MOTOR ACTIVITY; NEUROCHEMISTRY; PREFRONTAL CORTEX; RATS; RATS, WISTAR; STARTLE REACTION; TETRAHYDROISOQUINOLINES;

EID: 74949124464     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12640-009-9097-y     Document Type: Article

References (109)

1. Abe K, Saitoh T, Horiguchi Y, Utsunomiya I, Taguchi K (2005) Synthesis and neurotoxicity of tetrahydroisoquinoline derivatives for studying Parkinsońs disease. Biol Pharm Bull 28:1355-1362
2. Abekawa T, Ito K, Koyama T (2006) Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidineinduced acute increases in glutamate levels in the rat medial prefrontal cortex. Naunyn Schmiedebergs Arch Pharmacol 374: 177-193
3. Abekawa T, Ito K, Koyama T (2007) Different effects of a single and repeated administration of clozapine on phencyclidine-induced hyperlocomotion and glutamate releases in the ratmedial prefrontal cortex at short-and long-term withdrawal from this antipsychotic. Naunyn Schmiedebergs Arch Pharmacol 375:261-271
4. Adams B, Moghaddam B (1998) Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J Neurosci 18:5545-5554
5. Antkiewicz-Michaluk L, Vetulani J (2001) Tetrahydroisoquinolines as endogenous neurotoxins and neuroprotectants. Acta Neurobiol Exp 61:246
6. Antkiewicz-Michaluk L, Michaluk J, Romańska I, Papla I, Vetulani J (2000) Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol. J Neural Transm 107:1009-1019
7. Antkiewicz-Michaluk L, Michaluk J, Mokrosz M, Romańska I, Lorenc-Koci E, Ohta S, Vetulani J (2001) Different action on dopamine catabolic pathways of two endogenous 1,2,3,4-tetrahydroisoquinolines with similar antidopaminergic properties. J Neurochem 78: 100-108
8. Antkiewicz-Michaluk L, Karolewicz B, Romańska I, Michaluk J, Bojarski AJ, Vetulani J (2003) 1-Methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain. Eur J Pharmacol 466:263-269
9. Antkiewicz-Michaluk L, Wardas J, Michaluk J, Romańska I, Bojarski A, Vetulani J (2004) Protective effect of 1-methyl-1,2,3,4- tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. Int J Neuropsychopharmacol 7:155-163
10. Antkiewicz-Michaluk L, Filip M, Kostowski W, Patsenka A, Popik P, Przegaliński E, Wróbel M (2005) 1-Methyl-1,2,3,4- tetrahydroisoquinoline attenuates ethanol, cocaine and morphine addiction in behavioral models: neurochemical correlates. Acta Neurobiol Exp 65:301-321
11. Antkiewicz-Michaluk L, Łazarewicz JW, Patsenka A, Kajta M, Ziemińska E, Salińska E, Wâsik A, Gołembiowska K, Vetulani J (2006) The mechanism of 1,2,3,4-tetrahydroisoquinolines neuroprotection: the importance of free radicals scavenging properties and inhibition of glutamate-induced excitotoxicity. J Neurochem 97:846-856
12. Antkiewicz-Michaluk L, Filip M, Michaluk J, Romańska I, Przegaliński E, Vetulani J (2007) An endogenous neuroprotectant substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), prevents the behavioral and neurochemical effects of cocaine reinstatement in drug-dependent rats. J Neural Transm 114:307-317
13. Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101
14. Bakshi VP, Geyer MA (1998) Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. J Neurosci 18:8394-8401
15. Bakshi VP, Geyer MA (1999) Alpha-1-adrenergic receptors mediate sensorimotor gating deficits produced by intracerebral dizocilpine administration in rats. Neuroscience 92:113-121
16. Bakshi VP, Swerdlow NR, Geyer MA (1994) Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271:787-794
17. Bast T, Zhang W, Feldon J, White IM (2000) Effects of MK801 and neuroleptics on prepulse inhibition: re-examination in two strains of rats. Pharmacol Biochem Behav 67:647-658
18. Braff DL, Geyer MA, Light GA, Sprock J, Perry W, Cadenhead KS, Swerdlow NR (2001a) Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res 49:171-178
19. Braff DL, Geyer MA, Swerdlow NR (2001b) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156: 234-258
20. Bubenikova V, Votava M, Horácek J, Pálenicek T, Dockery C (2005) The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating. Pharmacol Biochem Behav 80:591-596
21. Bubser M, Koch M (1994) Prepulse inhibition of the acoustic startle response of rats is reduced by 6-hydroxydopamine lesions of the medial prefrontal cortex. Psychopharmacology (Berl) 113:487-492
22. Clineschmidt BV, Martin GE, Bunting PR, Papp NL (1982) Central sympathomimetic activity of (?)-5-methyl-10,11-dihydro-5Hdibenzo [a, d] cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic and apparent anxiolytic properties. Drug Dev Res 2:135
23. De Jong IE, van den Buuse M (2006) SCH 23390 in the prefrontal cortex enhances the effect of apomorphine on prepulse inhibition of rats. Neuropharmacology 51:438-446
24. Duncan EJ, Szilagyi S, Efferen TR, Schwartz MP, Parwani A, Chakravorty S, Madonick SH, Kunzova A, Harmon JW, Angrist B, Gonzenbach S, Rotrosen JP (2003) Effect of treatment status on prepulse inhibition of acoustic startle in schizophrenia. Psychopharmacology (Berl) 167:63-71
25. Ellenbroek BA, Budde S, Cools AR (1996) Prepulse inhibition and latent inhibition: the role of dopamine in the medial prefrontal cortex. Neuroscience 75:535-542
26. Enomoto T, Ishibashi T, Tokuda K, Ishiyama T, Toma S, Ito A (2008) Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radialarm maze tests in rats. Behav Brain Res 186:197-207
27. Fendt M, Schwienbacher I, Koch M (2000) Amygdaloid N-methyl-Daspartate and gamma-aminobutyric acid(A) receptors regulate sensorimotor gating in a dopamine-dependent way in rats. Neuroscience 98:55-60
28. Garcia-Ladona FJ, Cox BF (2003) BP897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction. CNS Drug Rev 9:141-158
29. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156:117-154
30. Goldman-Rakic PS, Muly EC, Williams GV (2000) D(1) receptors in prefrontal cells and circuits. Brain Res Rev 31:295-301
31. Gołembiowska K, Dziubina A (2004) Striatal adenosine A2A receptor blockade increases extracellular dopamine release following L-DOPA administration in intact and dopamine-denervated rats. Neuropharmacology 47:414-426
32. Green MF (2007) Stimulating the development of drug treatments to improve cognition in schizophrenia. Annu Rev Clin Psychol 3:159-180
33. Hoffman DC (1992) Typical and atypical neuroleptics antagonize MK- 801-induced locomotion and stereotypy in rats. J Neural Transm Gen Sect 89:1-10
34. Hoffman DC, Donovan H, Cassella JV (1993) The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801. Psychopharmacology (Berl) 111:339-344
35. Homayoun H, Stefani MR, Adams BW, Tamagan GD, Moghaddam B (2004) Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 29: 1259-1269
36. Hondo H, Yonezawa Y, Nakahara K, Hirano M, Uchimura H, Tashiro N (1994) Effect of phencyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study. Brain Res 633: 337-342
37. Imre G, Fokkema DS, Ter Horst GJ (2006a) Subchronic administration of LY354740 does not modify ketamine-evoked behavior and neuronal activity in rats. Eur J Pharmacol 544:77-81
38. Imre G, Salomons A, Jongsma M, Fokkema DS, Den Boer JA, Ter Horst GJ (2006b) Effects of the mGluR2/3 agonist LY379268 on ketamine-evoked behaviours and neurochemical changes in the dentate gyrus of the rat. Pharmacol Biochem Behav 84: 392-399
39. Jackson DM, Johansson C, Lindgren LM, Bengtsson A (1994a) Dopamine receptor antagonists block amphetamine and phencyclidine-induced motor stimulation in rats. Pharmacol Biochem Behav 48:465-471
40. Jackson DM, Ryan C, Evenden J, MohellN(1994b) Preclinical findings with new antipsychotic agents: what makes them atypical? Acta Psychiatr Scand Suppl 380:41-48
41. Jackson ME, Homayoun H, Moghaddam B (2004) NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci USA 101:8467-8472
42. Jentsch JD, Wise A, Katz Z, Roth RH (1998) Alpha-noradrenergic receptor modulation of the phencyclidine-and delta9-tetrahydrocannabinol-induced increases in dopamine utilization in rat prefrontal cortex. Synapse 28:21-26
43. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA, CATIE Investigators, Neurocognitive Working Group (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 64:633-647
44. Keith VA, Mansbach RS, Geyer MA (1991) Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry 30:557-566
45. Koch M, Bubser M (1994) Deficient sensorimotor gating after 6-hydroxydopamine lesion of the rat medial prefrontal cortex is reversed by haloperidol. Eur J Neurosci 6:1837-1845
46. Kristiansen LV, Huerta I, Beneyto M, Meador-Woodruff JH (2007) NMDAreceptors and schizophrenia. Curr Opin Pharmacol 7:48-55
47. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214
48. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R (2003) NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 169:215-233
49. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, McDougall L, Hunsberger T, Belger A, Levine L, Breier A (2005) Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 179:303-309
50. Kumari V, Soni W, Sharma T (1999) Normalization of information processing deficits in schizophrenia with clozapine. Am J Psychiatry 156:1046-1051
51. Lacroix L, Broersen LM, Feldon J, Weiner I (2000) Effects of local infusions of dopaminergic drugs into the medial prefrontal cortex of rats on latent inhibition, prepulse inhibition and amphetamine induced activity. Behav Brain Res 107:111-121
52. Le Foll B, Schwartz JC, Sokoloff P (2000) Dopamine D3 receptor agents as potential new medications for drug addiction. Eur Psychiatry 15:140-146
53. Le Foll B, Goldberg SR, Sokoloff P (2005) The dopamine D3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology 49:525-541
54. López-Gil X, Babot Z, Amargós-Bosch M, Suñol C, Artigas F, Adell A (2007) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17:141-150
55. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959) Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 81:363-369
56. Ma J, Leung LS (2007) The supramammillo-septal-hippocampal pathway mediates sensorimotor gating impairment and hyperlocomotion induced by MK-801 and ketamine in rats. Psychopharmacology (Berl) 191:961-974
57. Ma J, Shen B, Rajakumar N, Leung LS (2004) The medial septum mediates impairment of prepulse inhibition of acoustic startle induced by a hippocampal seizure or phencyclidine. Behav Brain Res 155:153-166
58. Mach UR, Hackling AE, Perachon S, Ferry S, Wermuth CG, Schwartz JC, Sokoloff P, Stark H (2004) Development of novel 1,2,3,4-tetrahydroisoquinoline derivatives and closely related compounds as potent and selective dopamine D3 receptor ligands. Chembiochem 5:508-518
59. Maj J, Rogóz Z, Skuza G (1991) Locomotor hyperactivity induced by MK-801 in rats. Pol J Pharmacol Pharm 43:449-458
60. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A (1997) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17:141-150
61. Mansbach RS, Geyer MA, Braff DL (1988) Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology (Berl) 94:507-514
62. Marcus MM, Jardemark KE, Wadenberg ML, Langlois X, Hertel P, Svensson TH (2005) Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. Int J Neuropsychopharmacol 8:315-327
63. Marrs W, Kuperman J, Avedian T, Roth RH, Jentsch JD (2005) Alpha-2 adrenoceptor activation inhibits phencyclidine-induced deficits of spatial working memory in rats. Neuropsychopharmacology 30: 1500-1510
64. McNaught KS, Carrupt PA, Altomare C, Cellamare S, Carotti A, Testa B, Jenner P, Meltzer HY (1994) An overview of the mechanism of action of clozapine. J Clin Psychiatr 55:47-52
65. Miller JW, Selhub J, Joseph JA (1996) Oxidative damage caused by free radicals produced during catecholamine autoxidation: protective effects of O-methylation and melatonin. Free Radic Biol Med 21:241-249
66. Moghaddam B, Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349-1352
67. Mouri A, Noda Y, Enomoto T, Nabeshima T (2007) Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int 51:173-184
68. Murphy BL, Arnsten AF, Jentsch JD, Roth RH (1996a) Dopamine and spatial working memory in rats and monkeys: pharmacological reversal of stress-induced impairment. J Neurosci 16: 7768-7775
69. Murphy BL, Arnsten AF, Goldman-Rakic PS, Roth RH (1996b) Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc Natl Acad Sci USA 93:1325-1329
70. Nagatsu T (1997) Isoquinoline neurotoxins in the brain and Parkinsońs disease. Neurosci Res 29:99-111
71. Narayanan S, Willins D, Dalia A, Wallace L, Uretsky N (1996) Role of dopaminergic mechanisms in the stimulatory effects of MK- 801 injected into the ventral tegmental area and the nucleus accumbens. Pharmacol Biochem Behav 54:565-573
72. Ogren SO, Goldstein M (1994) Phencyclidine-and dizocilpineinduced hyperlocomotion are differentially mediated. Neuropsychopharmacology 11:167-177
73. Olanow CW (1992) An introduction to the free radical hypothesis in Parkinsońs disease. Ann Neurol Suppl 32:S2-S9
74. Ossowska K, Pietraszek M, Wardas J, Nowak G, Zajaczkowski W, Wolfarth S, Pilc A (2000) The role of glutamate receptors in antipsychotic drug action. Amino Acids 19:87-94
75. Ouagazzal A, Nieoullon A, Amalric M (1994) Locomotor activation induced by MK-801 in the rat: postsynaptic interactions with dopamine receptors in the ventral striatum. Eur J Pharmacol 251:229-236
76. Patsenka A, Antkiewicz-Michaluk L (2004) Inhibition of rodent brain monoamine oxidase and tyrosine hydroxylase by endogenous compounds-1,2,3,4- tetrahydroisoquinoline alkaloids. Pol J Pharmacol 56:727-734
77. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic Press, San Diego
78. Peuskens J, Demily C, Thibaut F (2005) Treatment of cognitive dysfunction in schizophrenia. Clin Ther Suppl A 27:S25-S37
79. Pouzet B, Didriksen M, Arnt J (2002) Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia. Pharmacol Biochem Behav 71:635-643 (Pubitemid 34219214)
80. Ragozzino ME, Unick KE, Gold PE (1996) Hippocampal acetylcholine release during memory testing in rats: augmentation by glucose. Proc Natl Acad Sci USA 93:4693-4698
81. Ragozzino ME, Adams S, Kesner RP (1998) Differential involvement of the dorsal anterior cingulated and prelimbic-infralimbic areas of the rodent prefrontal cortex in spatial working memory. Behav Neurosci 112:293-303
82. Reijmers LG, Vanderheyden PM, Peeters BW (1995) Changes in prepulse inhibition after local administration of NMDA receptor ligands in the core region of the rat nucleus accumbens. Eur J Pharmacol 272:131-138
83. Schmidt CJ, Fadayel GM (1996) Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade. J Pharmacol Exp Ther 277:1541-1549
84. Schwabe K, Koch M (2004) Role of the medial prefrontal cortex in Nmethyl-D-aspartate receptor antagonist induced sensorimotor gating deficit in rats. Neurosci Lett 355:5-8
85. Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1(2):133-152
86. Siuciak JA, McCarthy SA, Chapin DS, Reed TM, Vorhees CV, Repaske DR (2007) Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme. Neuropharmacology 53:113-124
87. Stone JM, Morrison PD, Pilowsky LS (2007) Glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review. J Psychopharmacol 21:440-452
88. Swerdlow NR, Braff DL, Masten VL, Geyer MA (1990a) Schizophrenic-like sensorimotor gating abnormalities in rats following dopamine infusion into the nucleus accumbens. Psychopharmacology (Berl) 101:414-420
89. Swerdlow NR, Mansbach RS, Geyer MA, Pulvirenti L, Koob GF, Braff DL (1990b) Amphetamine disruption of prepulse inhibition of acoustic startle is reversed by depletion of mesolimbic dopamine. Psychopharmacology (Berl) 100:413-416
90. Swerdlow NR, Keith VA, Braff DL, Geyer MA (1991) Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat. J Pharmacol Exp Ther 256:530-536
91. Swerdlow NR, Braff DL, Taaid N, Geyer MA (1994a) Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51:139-154
92. Swerdlow NR, Zisook D, Taaid N (1994b) Seroquel (ICI 204, 636) restores prepulse inhibition of acoustic startle in apomorphinetreated rats: similarities to clozapine. Psychopharmacology (Berl) 114:675-678
93. Swerdlow NR, Geyer MA, Braff DL (2001) Neural circuitry of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 156:194-215
94. Swerdlow NR, Shoemaker JM, Kuczenski R, Bongiovanni MJ, Neary AC, Tochen LS, Saint Marie RL (2006) Forebrain D1 function and sensorimotor gating in rats: effects of D1 blockade, frontal lesions and dopamine denervation. Neurosci Lett 402:40-45
95. Swerdlow NR, Shoemaker JM, Bongiovanni MJ, Neary AC, Tochen LS, Saint Marie RL (2007) Strain differences in the disruption of prepulse inhibition of startle after systemic and intra-accumbens amphetamine administration. Pharmacol Biochem Behav 87:1-10
96. Tasaki Y, Makino Y, Ohta S, Hirobe M (1991) 1-Methyl-1,2,3,4- tetrahydroisoquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated mouse, prevents parkinsonism-like behavior abnormalities. J Neurochem 57:1940-1943
97. Varty GB, Bakshi VP, Geyer MA (1999) M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats. Neuropsychopharmacology 20:311-321
98. Verma A, Moghaddam B (1996) NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 16:373-379
99. Vetulani J, Antkiewicz-Michaluk L, Nalepa I, Sansone M (2003) A possible physiological role for cerebral tetrahydroisoquinolines. Neurotoxicity Res 5:147-155
100. Wasik A, Romańska I, Antkiewicz-Michaluk L (2007) The effect of an endogenous compound 1-methyl-1,2,3,4-tetrahydroisoquinoline on morphine-induced analgesia, dependence and neurochemical changes in dopamine metabolism in rat brain structures. J Physiol Pharmacol 58:235-252
101. Wedzony K, Golembiowska K, Klimek V (1993a) MK-801-induced symptoms of sensitization. The lack of correlation with the extracellular concentration of dopamine in the rat prefrontal cortex. Brain Res 625:333-336 (Pubitemid 23300432)
102. Wedzony K, Klimek V, Golembiowska K (1993b) MK-801 elevates the extracellular concentration of dopamine in the rat prefrontal cortex and increases the density of striatal dopamine D1 receptors. Brain Res 622:325-329 (Pubitemid 23264985)
103. Wedzony K, Golembiowska K, Zazula M (1994) Differential effects of CGP 37849 and MK-801, competitive and noncompetitive NMDA antagonists, with respect to the modulation of sensorimotor gating and dopamine outflow in the prefrontal cortex of rats. Naunyn Schmiedebergs Arch Pharmacol 350:555-562
104. Wynn JK, Green MF, Sprock J, Light GA, Widmark C, Reist C, Erhart S, Marder SR, Mintz J, Braff DL (2007) Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res 95:134-142
105. Yamakawa T, Ohta S (1997) Isolation of 1-methyl-1,2,3,4- tetrahydroisoquinoline-synthesizing enzyme from rat brain: a possible Parkinsońs disease-preventing enzyme. Biochem Biophys Res Commun 236:676-681
106. Yamakawa T, Ohta S (1999) Biosynthesis of a parkinsonismpreventing substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline, is inhibited by parkinsonism-inducing compounds in rat brain mitochondrial fraction. Neurosci Lett 259:157-160
107. Yamakawa T, Kotake Y, Fuijtani M, Shintani H, Makino Y, Otha S (1999) Regional distribution of parkinsonism-preventing endogenous tetrahydroisoquinoline derivatives and an endogenous parkinsonism-preventing substance-synthesizing enzyme in monkey brain. Neurosci Lett 276:68-70
108. Zahrt J, Taylor JR, Mathew RG, Arnsten AF (1997) Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci 17:8528-8535
109. Zavitsanou K, Cranney J, Richardson R (1999) Dopamine antagonists in the orbital prefrontal cortex reduce prepulse inhibition of the acoustic startle reflex in the rat. Pharmacol Biochem Behav 63:55-61